AstraZeneca Annual Report and Financial Statements Form 20-F Information 2004 89 11 Fixed asset investments continued Share of joint venture assets and liabilities 2004 2003 $m $m Gross assets 174 Gross liabilities 174 The group disposed of its joint venture Advanta BV on 1 September 2004.
The profit on disposal is disclosed in Note 3.
12 Stocks 2004 2003 $m $m Raw materials and consumables 646 715 Stocks in process 970 1,206 Finished goods and goods for resale 1,404 1,101 3,020 3,022 13 Debtors 2004 2003 $m $m Amounts due within one year Trade debtors 3,636 3,260 Less: Amounts provided for doubtful debts 46 57 3,590 3,203 Deferred taxation Note 5 623 732 Other debtors 492 508 Prepayments and accrued income 1,110 1,093 5,815 5,536 Amounts due after more than one year Deferred taxation Note 5 159 165 Other debtors 78 32 Prepayments and accrued income 222 227 459 424 6,274 5,960 Figures include prepaid pension costs Note 28.
Provisions for doubtful debts 2004 2003 2002 $m $m $m Balance at beginning of year 57 56 42 Profit and loss account charge 811 Amounts utilised and other movements 11 7 3 Balance at end of year 46 57 56
